nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

VB2 cell fate analysis of <i>hlh-17</i>, <i>hlh-31</i>, and <i>hlh-32</i> mutant animals. by G. Robert Aguilar (13889674)

Clinical and Imaging Characteristics of Posterior Scleritis in Children by Ayala Katzir (20605679)

“…Retinal nerve fiber layer (RNFL) was thickened in all examined eyes (mean±SD 136.2 ± 28.4 µm) at presentation and it significantly decreased with treatment (109.8 ± 8.2 µm two months later). …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…Mean steps per 24 h was 3,359 (range 1,493–6,277) at baseline. …”

Data Sheet 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by figshare admin frontiersin (4545187)

“…Mean steps per 24 h was 3,359 (range 1,493–6,277) at baseline. …”

Data Sheet 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by Øystein Fluge (200378)

“…Mean steps per 24 h was 3,359 (range 1,493–6,277) at baseline. …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…Mean steps per 24 h was 3,359 (range 1,493–6,277) at baseline. …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…Mean steps per 24 h was 3,359 (range 1,493–6,277) at baseline. …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…Mean steps per 24 h was 3,359 (range 1,493–6,277) at baseline. …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…Mean steps per 24 h was 3,359 (range 1,493–6,277) at baseline. …”

Table 3_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.docx by Jia-Yi Wang (490704)

“…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”

Table 2_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx by Jia-Yi Wang (490704)

“…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”

Table 1_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx by Jia-Yi Wang (490704)

“…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”